Paper39796264
A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases.
Khoon L and 1 other. Int J Mol Sci, 2025. Cited by 8 papers, by iCite.
Cite this record
ConductScience Library. A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases. Papers, record 39796264. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/39796264
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- A New Strategy in Modulating the Protease-Activated Receptor 2 (Par2) in Autoimmune Diseases.
- PubMed
Topics8
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Receptor, PAR-2 | Major topic |
| Autoimmune Diseases | Major topic |
| Humans | |
| Animals | |
| Signal Transduction | |
| Inflammation | |
| Diabetes Mellitus, Type 1 | |
| Inflammatory Bowel Diseases |
Source PubMed
References89
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 33763056 | Proteinase-Mediated Macrophage Signaling in Psoriatic Arthritis. | Front Immunol | 2020 | https://conductscience.org/library/papers/33763056 | PubMed |
| 2 | 39301020 | Protease-Activated Receptor 2 in inflammatory skin disease: current evidence and future perspectives. | Front Immunol | 2024 | https://conductscience.org/library/papers/39301020 | PubMed |
| 3 | 38670065 | Principles and therapeutic applications of adaptive immunity. | Cell | 2024 | https://conductscience.org/library/papers/38670065 | PubMed |
| 4 | 27156434 | Rheumatoid arthritis. | Lancet | 2016 | https://conductscience.org/library/papers/27156434 | PubMed |
| 5 | 33823532 | Deficiency of protease-activated receptor (PAR) 1 and PAR2 exacerbates collagen-induced arthritis in mice via differing mechanisms. | Rheumatology (Oxford) | 2021 | https://conductscience.org/library/papers/33823532 | PubMed |
| 6 | 16039337 | Sjögren's syndrome. | Lancet | 2005 | https://conductscience.org/library/papers/16039337 | PubMed |
| 7 | 12795636 | A novel serine protease predominately expressed in macrophages. | Biochem J | 2003 | https://conductscience.org/library/papers/12795636 | PubMed |
| 8 | 3675011 | Experimental autoimmune arthritis in mice. I. Homologous type II collagen is responsible for self-perpetuating chronic polyarthritis. | Ann Rheum Dis | 1987 | https://conductscience.org/library/papers/3675011 | PubMed |
| 9 | 30448290 | Systemic lupus erythematosus: Diagnosis and clinical management. | J Autoimmun | 2019 | https://conductscience.org/library/papers/30448290 | PubMed |
| 10 | 16847277 | Type 1 diabetes: pathogenesis and prevention. | CMAJ | 2006 | https://conductscience.org/library/papers/16847277 | PubMed |
| 11 | 34294936 | Pathology of autoimmune hepatitis. | Pathologica | 2021 | https://conductscience.org/library/papers/34294936 | PubMed |
| 12 | 24415853 | Immunopathology of inflammatory bowel disease. | World J Gastroenterol | 2014 | https://conductscience.org/library/papers/24415853 | PubMed |
| 13 | 34930943 | The activation fragment of PAR2 is elevated in serum from patients with rheumatoid arthritis and reduced in response to anti-IL6R treatment. | Sci Rep | 2021 | https://conductscience.org/library/papers/34930943 | PubMed |
| 14 | 36618407 | Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. | Front Immunol | 2022 | https://conductscience.org/library/papers/36618407 | PubMed |
| 15 | 23647384 | Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. | J Neurochem | 2013 | https://conductscience.org/library/papers/23647384 | PubMed |
| 16 | 15655521 | 2-Furoyl-LIGRL-NH2, a potent agonist for proteinase-activated receptor-2, as a gastric mucosal cytoprotective agent in mice. | Br J Pharmacol | 2005 | https://conductscience.org/library/papers/15655521 | PubMed |
| 17 | 37131291 | Crohn's disease proteolytic microbiota enhances inflammation through PAR2 pathway in gnotobiotic mice. | Gut Microbes | 2023 | https://conductscience.org/library/papers/37131291 | PubMed |
| 18 | 15475570 | Multiple independent functions of arrestins in the regulation of protease-activated receptor-2 signaling and trafficking. | Mol Pharmacol | 2005 | https://conductscience.org/library/papers/15475570 | PubMed |
| 19 | 33120736 | Targeting of protease activator receptor-2 (PAR-2) antagonist FSLLRY-NH2 as an asthma adjuvant therapy. | Medicine (Baltimore) | 2020 | https://conductscience.org/library/papers/33120736 | PubMed |
| 20 | 32682869 | Treatment of Multiple Sclerosis: A Review. | Am J Med | 2020 | https://conductscience.org/library/papers/32682869 | PubMed |
Cited by5
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 8 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42737495 | PhageScout: Protease Cleavage Site Prediction Using an Experimental Substrate Phage Display Motif-Based Approach. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42737495 | PubMed |
| 42693238 | Proteomic analysis of pancreatic endocrine cells by mechanistic single-cell isolation identifies membrane pathways. | Exp Mol Med | 2026 | https://conductscience.org/library/papers/42693238 | PubMed |
| 41002416 | Curcumin Inhibits Protease Activated Receptor 2-Induced ERK Phosphorylation Calcium Mobilization and Anti-Apoptotic Signaling in Inflammation-Driven Colorectal Cancer Cells. | Cells | 2025 | https://conductscience.org/library/papers/41002416 | PubMed |
| 40487592 | Neuroprotection induced by protease-activated receptor 2 activation is independent of Gq signalling. | Brain Neurosci Adv | 2025 | https://conductscience.org/library/papers/40487592 | PubMed |
| 39891111 | Protease-activated receptors in vascular smooth muscle cells: a bridge between thrombo-inflammation and vascular remodelling. | Cell Commun Signal | 2025 | https://conductscience.org/library/papers/39891111 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| F2RL1 | 2150 | PubTator's text mining | https://conductscience.org/library/genes/2150 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/39796264
GET https://conductscience.org/api/papers/v1/39796264/references?page=2